Actively Recruiting
Tissue and Metabolic Characterization of Arrhythmogenic Cardiomyopathies by Hybrid PET-MRI Imaging, Impact of the Observed Profiles on the Phenotype and on the Evolution of Cardiomyopathy
Led by Nantes University Hospital · Updated on 2026-04-17
80
Participants Needed
5
Research Sites
226 weeks
Total Duration
On this page
Sponsors
N
Nantes University Hospital
Lead Sponsor
U
University Hospital, Brest
Collaborating Sponsor
AI-Summary
What this Trial Is About
Status of the research project: The main complications of arrhythmogenic cardiomyopathies (AC) are sudden death, more rarely heart failure. Recently, data are emerging in favor of an associated role of myocardial inflammation and myocarditis in this pathology, but the impact of inflammation on the presentation and prognosis of the cardiomyopathy, as well as its mechanisms, are not clearly elucidated. To date, endomyocardial biopsy is the gold standard for documenting myocardial inflammation. Aim of the research: To evaluate the interest of a new hybrid PET-MR imaging tool for tissue and metabolic characterization of AC associating MRI and 18F-FDG PET, already used in inflammatory pathologies (cardiac sarcoidosis). Project description: Multicentric observational study of 80 patients with genetic AC undergoing PET-MR. Description of the observed profiles and their impact on the phenotype of the cardiomyopathy and its evolution, study of associated immunological mechanisms, correlation with available anatomopathological data. Expected results and perspectives: first non-invasive description of tissue and metabolic phenotype of AC by PET-MR imaging and its prognostic role, basis for pathophysiological and therapeutic research in case of confirmation of the performances of this imaging for the detection of myocardial inflammation.
CONDITIONS
Official Title
Tissue and Metabolic Characterization of Arrhythmogenic Cardiomyopathies by Hybrid PET-MRI Imaging, Impact of the Observed Profiles on the Phenotype and on the Evolution of Cardiomyopathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male and female over 16 years old
You will not qualify if you...
- Patients and their relatives with left ventricular or biventricular AC carrying pathogenic or likely pathogenic variants in specified genes (PKP2, DSG2, DSC2, JUP, DSP, DES, FLNC, PLN, LMNA, TMEM43, CDH2, BAG3, RYR2, RBM20)
- Diagnosis of sarcoidosis or any known autoimmune disease
- History of myocardial infarction
- Patient under guardianship, curatorship, or safeguard of justice
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
CHU Angers
Angers, France, 49000
Actively Recruiting
2
CHU Brest
Brest, France, 29000
Actively Recruiting
3
CHU de Nantes
Nantes, France, 44093
Actively Recruiting
4
AP-HP La Salpêtrière
Paris, France, 75013
Actively Recruiting
5
CHU de Rennes
Rennes, France, 35000
Actively Recruiting
Research Team
N
Nicolas Piriou, PH
CONTACT
A
Aurélie Thollet
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here